@ARTICLE{
author={Verschraegen C,Andric Zoran G,Moiseenko FV,Makharadze T,Oleksiienko A,Ruiz EP Yanez,Kim SH,Ahn K,Park TH,Ju HA,Baek EH,Kwon S,Lee SJ,Chang I,Kim SH,Kim HA,Lee E,Ohe Y},
year={2024},
title={3-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer},
journal={ANNALS OF ONCOLOGY},
volume={35},
number={},
pages={S1648-S1649},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Kao SCH,Reck M,Liu SV,Dziadziuszko R,Hochmair MJ,Huemer F,Gilberto de Castro J,Bernabe Caro R,Kim SH,Kowalski DM,Andric Zoran G,Oancea M,Kaul M,Li H,Danner B,Lee MC,Nabet BY,Sugawara S},
year={2024},
title={Whole exome sequencing (WES) analyses from IMpower133 and 6-year (y) overall survival (OS) from IMbrella A in patients (pts) with extensive-stage small cell lung cancer (ESSCLC) treated with atezolizumab (atezo)},
journal={ANNALS OF ONCOLOGY},
volume={35},
number={},
pages={S1638-S1638},
document_type={Meeting Abstract},
}